As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Roivant Sciences Ltd (ROIV) showcases robust financial health with $5.4 billion in cash and no debt, while navigating competitive pressures and strategic opportunities.

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.